Genprex Narrows Q2 Loss Amidst Clinical Trial Progress, Cash Declines

Ticker: GNPX · Form: 10-Q · Filed: Aug 14, 2025 · CIK: 1595248

Sentiment: mixed

Topics: Biotechnology, Gene Therapy, Oncology, Clinical Trials, NSCLC, SCLC, Diabetes, Cash Burn, FDA Fast Track

Related Tickers: AZN, MRK, RHHBY

TL;DR

**GNPX is burning cash fast, but narrowing losses and clinical trial progress in lung cancer could be a lifeline if they can secure more funding.**

AI Summary

Genprex, Inc. (GNPX) reported a net loss of $4,674,901 for the three months ended June 30, 2025, an improvement from a net loss of $6,495,845 in the same period of 2024. For the six months ended June 30, 2025, the net loss was $8,639,503, compared to $12,464,714 in the prior year. Research and development expenses increased to $2,499,495 for the three months ended June 30, 2025, from $1,666,522 in 2024, while general and administrative expenses significantly decreased to $2,182,289 from $4,849,472. The company's cash and cash equivalents decreased to $1,346,844 as of June 30, 2025, from $1,601,660 at December 31, 2024. Genprex is actively enrolling patients in the Phase 2a expansion of its Acclaim-1 clinical trial for NSCLC and the Phase 2 expansion of its Acclaim-3 trial for ES-SCLC, both of which have FDA Fast Track Designation. The Acclaim-2 trial for NSCLC was ceased due to enrollment challenges. The company also continues preclinical studies for its GPX-002 diabetes gene therapy, with plans to seek further FDA guidance in the second half of 2025.

Why It Matters

Genprex's ability to reduce its net loss while advancing key clinical trials, Acclaim-1 and Acclaim-3, is a mixed signal for investors. The significant decrease in general and administrative expenses suggests a focus on cost control, but the increase in R&D indicates continued investment in its pipeline. The cessation of the Acclaim-2 trial highlights the competitive landscape and challenges in patient enrollment within the oncology space, potentially impacting future market share against larger pharmaceutical companies like AstraZeneca and Merck & Co. For employees and customers, progress in Acclaim-1 and Acclaim-3 offers hope for new treatment options in lung cancer, especially with FDA Fast Track Designation, but the dwindling cash reserves raise questions about long-term operational sustainability and future funding needs.

Risk Assessment

Risk Level: high — Genprex reported a net loss of $8,639,503 for the six months ended June 30, 2025, and its cash and cash equivalents stood at only $1,346,844. This low cash balance, coupled with ongoing significant R&D expenses of $5,039,489 for the six-month period, indicates a high risk of needing additional capital to fund operations and complete clinical trials, potentially leading to further dilution for existing shareholders.

Analyst Insight

Investors should monitor Genprex's cash burn rate and upcoming financing activities closely. While clinical trial progress in Acclaim-1 and Acclaim-3 is positive, the current cash position suggests a high probability of further equity raises. Consider this a speculative investment with significant upside if trials succeed, but also substantial downside risk due to financial constraints.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
$3,827,524
total Debt
$0
net Income
-$4,674,901
eps
-$0.17
gross Margin
N/A
cash Position
$1,346,844
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Genprex's current cash position and how does it compare to previous periods?

As of June 30, 2025, Genprex's cash and cash equivalents were $1,346,844. This represents a decrease from $1,601,660 at December 31, 2024, and a significant drop from $2,459,024 at June 30, 2024, indicating a declining cash balance.

What are the key developments in Genprex's Acclaim-1 clinical trial?

Genprex is enrolling and treating patients in the Phase 2a expansion portion of its Acclaim-1 trial for NSCLC, combining REQORSA with Tagrisso. The trial focuses on patients who progressed on Tagrisso or Tagrisso-containing regimens, with an interim analysis expected in the first half of 2026 after 19 patients are treated.

Why did Genprex cease enrollment in the Acclaim-2 trial?

Genprex ceased enrollment of new patients in the Acclaim-2 trial due to enrollment challenges and delays, including competition for investigators and eligible patients with numerous other trials involving the same patient population. This decision was made to prioritize resources for the other two Acclaim trials.

What is the status of Genprex's Acclaim-3 clinical trial?

The Acclaim-3 trial for ES-SCLC is currently in its Phase 2 expansion portion, enrolling approximately 50 patients. The trial, which combines REQORSA with Tecentriq, has received FDA Fast Track Designation and Orphan Drug Designation, with a futility analysis planned after the 25th patient reaches 18 weeks of follow-up.

How have Genprex's operating expenses changed year-over-year?

For the six months ended June 30, 2025, total operating expenses were $8,651,076, down from $12,515,000 in the same period of 2024. This reduction was primarily driven by a decrease in general and administrative expenses from $7,569,140 to $3,611,587, despite an increase in research and development expenses from $4,940,902 to $5,039,489.

What is the strategic outlook for Genprex's diabetes gene therapy program?

Genprex is continuing preclinical studies for its GPX-002 diabetes gene therapy with the University of Pittsburgh. The company plans to initiate research in Type 2 diabetes animal models and expects to seek further regulatory guidance from the FDA on IND-enabling studies in the second half of 2025.

What are the primary risks associated with investing in Genprex?

Primary risks include Genprex's significant accumulated deficit of $163,438,946, its limited cash reserves of $1,346,844, and its reliance on successful clinical trial outcomes. The company's ability to continue as a going concern is dependent on obtaining additional financing, which could lead to further shareholder dilution.

How many shares of common stock does Genprex have outstanding?

As of August 1, 2025, Genprex had 33,466,784 shares of common stock, par value $0.001 per share, outstanding. This is a substantial increase from 10,860,655 shares outstanding at December 31, 2024.

What is REQORSA and what is its mechanism of action?

REQORSA gene therapy (quaratusugene ozeplasmid) is Genprex's lead oncology drug candidate. It utilizes the TUSC2 gene delivered via the ONCOPREX Delivery System to harm cancer cell metabolism, interrupt cell signaling pathways, re-establish apoptosis, and increase immune response against cancer cells.

Has Genprex received any special designations from the FDA for its drug candidates?

Yes, the FDA has granted Fast Track Designation for the Acclaim-1 treatment combination of REQORSA and Tagrisso in NSCLC patients. Additionally, the Acclaim-3 clinical trial for ES-SCLC has received both FDA Fast Track Designation and an FDA Orphan Drug Designation.

Risk Factors

Industry Context

The biopharmaceutical industry, particularly in oncology and gene therapy, is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies like Genprex operate in a competitive landscape where innovation is key, but clinical trial success and regulatory approval are paramount. Advances in personalized medicine and targeted therapies are driving new treatment paradigms.

Regulatory Implications

Genprex's drug candidates are subject to stringent FDA review. The Fast Track Designation for its lead programs is positive, but the company must navigate complex clinical trial requirements and demonstrate safety and efficacy to gain market approval. Any setbacks in regulatory processes could severely impact the company's valuation and future.

What Investors Should Do

  1. Monitor cash burn and future financing needs.
  2. Evaluate clinical trial progress and enrollment rates.
  3. Assess the competitive landscape and potential market penetration.
  4. Consider the impact of share dilution.

Key Dates

Glossary

NSCLC
Non-Small Cell Lung Cancer (Genprex is pursuing treatments for this common form of lung cancer through its Acclaim-1 and Acclaim-2 trials.)
ES-SCLC
Extensive Stage Small Cell Lung Cancer (Genprex is developing treatments for this aggressive form of lung cancer via its Acclaim-3 trial.)
FDA Fast Track Designation
A process by which the FDA expedites the development and review of drugs intended to treat serious conditions and fill unmet medical needs. (This designation for Acclaim-1 and Acclaim-3 trials suggests the FDA recognizes the potential of Genprex's therapies.)
REQORSA RP2D
Recommended Phase 2 Dose for REQORSA, the highest dose delivered in trials. (Indicates the dose level being advanced into further clinical testing for efficacy and safety.)
PFS
Progression-Free Survival (A key metric in oncology trials measuring the length of time during which a patient's cancer does not worsen. A 36-month PFS is a significant positive indicator.)
Accumulated Deficit
The cumulative net losses of a company since its inception, minus any cumulative net gains. (A high accumulated deficit, like Genprex's $163.4M, is typical for early-stage biotech firms but signifies a long path to profitability.)
Additional Paid-In Capital
The amount investors have paid for stock above its par or stated value. (Represents capital raised through equity offerings, which has been substantial for Genprex ($164.8M).)

Year-Over-Year Comparison

Genprex reported a narrower net loss for both the three-month ($4.67M vs $6.50M) and six-month ($8.64M vs $12.46M) periods ended June 30, 2025, compared to the prior year. This improvement is driven by a significant reduction in general and administrative expenses, which fell from $4.85M to $2.18M in Q2, despite an increase in research and development expenses from $1.67M to $2.50M. Total assets decreased slightly, and cash reserves also saw a reduction, indicating continued reliance on external funding.

Filing Stats: 4,487 words · 18 min read · ~15 pages · Grade level 16.9 · Accepted 2025-08-14 16:31:14

Key Financial Figures

Filing Documents

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 3 Consolidated Condensed Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 3 Consolidated Condensed Statements of Operations for the Three and Six Months Ended June 30, 2025, and 2024 (unaudited) 4 Consolidated Condensed Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2025, and 2024 (unaudited) 5 Consolidated Condensed Statements of Cash Flows for the Six Months Ended June 30, 2025, and 2024 (unaudited) 6 Notes to Unaudited Consolidated Condensed Financial Statements 7 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 21 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 29 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 29 PART II OTHER INFORMATION 30 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 30 ITEM 1A.

RISK FACTORS

RISK FACTORS 30 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 30 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 30 ITEM 4. MINE SAFETY DISCLOSURES 30 ITEM 5. OTHER INFORMATION 30 ITEM 6. EXHIBITS 30

SIGNATURES

SIGNATURES 32 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Genprex, Inc. Consolidated Condensed Balance Sheets June 30, December 31, 2025 2024 Assets (unaudited) (see Note 2) Current assets: Cash and cash equivalents $ 1,346,844 $ 1,601,660 Prepaid expenses and other 709,340 475,807 Total current assets 2,056,184 2,077,467 Other non-current assets: Research and development supplies 1,771,340 2,046,858 Total other assets 1,771,340 2,046,858 Total assets $ 3,827,524 $ 4,124,325 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 930,812 $ 1,074,295 Other current liabilities 1,505,517 1,429,875 Total current liabilities 2,436,329 2,504,170 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock $ 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively — — Common stock $ 0.001 par value: 200,000,000 shares authorized; 33,145,048 and 10,860,655 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 33,145 10,861 Additional paid-in capital 164,796,996 156,408,737 Accumulated deficit ( 163,438,946 ) ( 154,799,443 ) Total stockholders' equity 1,391,195 1,620,155 Total liabilities and stockholders' equity $ 3,827,524 $ 4,124,325 See accompanying notes to the unaudited consolidated condensed financial statements. 3 Table of Contents Genprex, Inc. Consolidated Condensed Statements of Operations (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Depreciation $ — $ 2,288 $ — $ 4,958 Research and development 2,499,495 1,666,522 5,039,489 4,940,902 General and administrative 2,182,289 4,849,472 3,611,587 7,569,140 Total operating expenses 4,681,784 6,518,282 8,651,076 12,515,000 Operating loss ( 4,681,784 ) ( 6,518,282 ) ( 8,651,076 ) ( 12,515,000 ) Oth

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing